$EVOK
Evoke Pharma Inc

2024 Q2 Form 10-Q Financial Statement

#000095017024059596 Filed on May 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q1
Revenue $2.551M $1.735M $810.4K
YoY Change 125.51% 114.15% 93.7%
Cost Of Revenue $41.48K $92.53K $50.59K
YoY Change -27.68% 82.9% 122.28%
Gross Profit $2.510M $1.643M $759.8K
YoY Change 133.69% 116.23% 92.06%
Gross Profit Margin 98.37% 94.67% 93.76%
Selling, General & Admin $3.733M $3.140M $2.848M
YoY Change 34.97% 10.24% 18.41%
% of Gross Profit 148.75% 191.09% 374.82%
Research & Development $0.00 $4.645K $66.99K
YoY Change -100.0% -93.07% 60.58%
% of Gross Profit 0.0% 0.28% 8.82%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $3.775M $3.237M $2.966M
YoY Change 29.46% 9.14% 20.08%
Operating Profit -$1.224M -$1.501M -$2.155M
YoY Change -31.43% -30.34% 5.07%
Interest Expense $124.7K $124.7K $123.3K
YoY Change 0.0% 1.11% -200.65%
% of Operating Profit
Other Income/Expense, Net -$43.66K -$78.60K -$87.96K
YoY Change -47.71% -10.64%
Pretax Income -$1.267M -$1.580M -$2.243M
YoY Change -32.16% -29.57% 3.19%
Income Tax
% Of Pretax Income
Net Earnings -$1.267M -$1.580M -$2.243M
YoY Change -32.16% -29.57% 3.19%
Net Earnings / Revenue -49.67% -91.03% -276.78%
Basic Earnings Per Share -$0.93 -$0.17 -$0.67
Diluted Earnings Per Share -$0.93 -$0.17 -$0.67
COMMON SHARES
Basic Shares Outstanding 8.597M 8.478M 3.343M
Diluted Shares Outstanding 1.364M 9.082M 3.343M

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.178M $9.703M $8.213M
YoY Change 30.99% 18.14% 6.64%
Cash & Equivalents $9.200M $9.700M $8.200M
Short-Term Investments
Other Short-Term Assets $27.68K $6.312K $11.55K
YoY Change 139.59% -45.36% -98.16%
Inventory $544.8K $588.8K $364.9K
Prepaid Expenses $382.9K $704.2K $671.4K
Receivables $2.003M $1.452M $687.3K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $12.14M $12.45M $9.948M
YoY Change 35.95% 25.19% 10.21%
LONG-TERM ASSETS
Property, Plant & Equipment $91.40K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00
YoY Change
Total Long-Term Assets $0.00 $0.00 $91.40K
YoY Change -100.0% -100.0%
TOTAL ASSETS
Total Short-Term Assets $12.14M $12.45M $9.948M
Total Long-Term Assets $0.00 $0.00 $91.40K
Total Assets $12.14M $12.45M $10.04M
YoY Change 35.15% 24.05% 11.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.184M $1.954M $1.186M
YoY Change 54.3% 64.76% 25.56%
Accrued Expenses $2.287M $265.9K $491.7K
YoY Change 243.57% -45.92% 19.27%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $5.000M
YoY Change
Total Short-Term Liabilities $9.471M $8.957M $1.678M
YoY Change 355.11% 433.91% 23.65%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $5.000M $5.000M
YoY Change -100.0% 0.0% 0.0%
Other Long-Term Liabilities $1.737M $1.236M
YoY Change 40.58% 67.97%
Total Long-Term Liabilities $0.00 $6.737M $6.236M
YoY Change -100.0% 8.04% 8.72%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.471M $8.957M $1.678M
Total Long-Term Liabilities $0.00 $6.737M $6.236M
Total Liabilities $9.471M $8.957M $7.913M
YoY Change 12.2% 13.19% 11.57%
SHAREHOLDERS EQUITY
Retained Earnings -$126.3M -$125.0M -$117.9M
YoY Change 5.45% 6.05%
Common Stock $129.0M $128.5M $120.0M
YoY Change 7.19% 7.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.500M $3.497M $2.126M
YoY Change
Total Liabilities & Shareholders Equity $12.14M $12.45M $10.04M
YoY Change 35.15% 24.05% 11.22%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q1
OPERATING ACTIVITIES
Net Income -$1.267M -$1.580M -$2.243M
YoY Change -32.16% -29.57% 3.19%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$820.6K -$2.579M -$1.631M
YoY Change -31.98% 58.16% 0.98%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 295.7K 7.543M 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -820.6K -2.579M -1.631M
Cash From Investing Activities
Cash From Financing Activities 295.7K 7.543M 0.000
Net Change In Cash -524.9K 4.963M -1.631M
YoY Change -56.49% -404.33% 12.98%
FREE CASH FLOW
Cash From Operating Activities -$820.6K -$2.579M -$1.631M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001403708
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2023#ProductMember
CY2023Q1 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2023#ProductMember
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-36075
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
EVOKE PHARMA, INC.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-8447886
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
420 Stevens Avenue
CY2024Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 370
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Solana Beach
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92075
CY2024Q1 dei City Area Code
CityAreaCode
858
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
345-1494
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2024Q1 dei Trading Symbol
TradingSymbol
EVOK
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8597405
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9702755
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4739426
CY2024Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2024Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
1451904
CY2023Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
673071
CY2024Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
704215
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
885040
CY2024Q1 us-gaap Inventory Net
InventoryNet
588776
CY2023Q4 us-gaap Inventory Net
InventoryNet
481840
CY2024Q1 us-gaap Other Assets Current
OtherAssetsCurrent
6312
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
47532
CY2024Q1 us-gaap Assets Current
AssetsCurrent
12453962
CY2023Q4 us-gaap Assets Current
AssetsCurrent
6826909
CY2023Q4 us-gaap Deferred Costs
DeferredCosts
241637
CY2024Q1 us-gaap Assets
Assets
12453962
CY2023Q4 us-gaap Assets
Assets
7068546
CY2024Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1953959
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1711778
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
265881
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1324010
CY2024Q1 us-gaap Notes Payable Current
NotesPayableCurrent
5000000
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
5000000
CY2024Q1 us-gaap Interest Payable Current
InterestPayableCurrent
1736953
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1612295
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
8956793
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9648083
CY2024Q1 us-gaap Liabilities
Liabilities
8956793
CY2023Q4 us-gaap Liabilities
Liabilities
9648083
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8597405
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8597405
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3343070
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3343070
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
859
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
334
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
128515568
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
120859567
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
254029
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
284572
CY2024Q1 us-gaap Interest Expense
InterestExpense
124658
CY2023Q1 us-gaap Interest Expense
InterestExpense
123288
CY2023Q1 evok Non Cash Lease Expense
NonCashLeaseExpense
37676
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
778833
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-125019258
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-123439438
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
3497169
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2579537
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12453962
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7068546
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1735490
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
810408
CY2024Q1 evok Cost Of Goods Sold Expenses
CostOfGoodsSoldExpenses
92529
CY2023Q1 evok Cost Of Goods Sold Expenses
CostOfGoodsSoldExpenses
50591
CY2024Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
4645
CY2023Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
66990
CY2024Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3139536
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2847940
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
3236710
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
2965521
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1501220
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2155113
CY2024Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
46058
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
35331
CY2024Q1 us-gaap Interest Expense
InterestExpense
124658
CY2023Q1 us-gaap Interest Expense
InterestExpense
123288
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-78600
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-87957
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1579820
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2243070
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.67
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.67
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9082139
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9082139
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3343070
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3343070
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2579537
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
254029
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6172623
CY2024Q1 evok Amendment And Issuance Of Common Stock And Pre Funded Warrants From Exercise Value
AmendmentAndIssuanceOfCommonStockAndPreFundedWarrantsFromExerciseValue
1229874
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1579820
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
3497169
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
4084649
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
284572
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2243070
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
2126151
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1579820
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2243070
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
62470
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-222045
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-281568
CY2024Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
106936
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
75489
CY2024Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
343596
CY2023Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
251613
CY2024Q1 evok Accrued Compensation
AccruedCompensation
1058129
CY2023Q1 evok Accrued Compensation
AccruedCompensation
190907
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-37676
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2579390
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1630895
CY2024Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
6718212
CY2024Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
426293
CY2024Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1250800
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7542719
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4963329
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1630895
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4739426
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9843699
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9702755
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8212804
CY2024Q1 evok Offering Costs Included In Accounts Payable
OfferingCostsIncludedInAccountsPayable
20926
CY2024Q1 evok Entity Incorporation Month And Year Of Incorporation
EntityIncorporationMonthAndYearOfIncorporation
2007-01
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9700000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
2100000
CY2024Q1 evok Proceeds From Issuance Of Common Stock Net Of Underwriting Discounts And Commissions And Offering Expenses
ProceedsFromIssuanceOfCommonStockNetOfUnderwritingDiscountsAndCommissionsAndOfferingExpenses
6200000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
1
CY2024Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2024Q1 evok Bad Debt Expense
BadDebtExpense
0
CY2023Q1 evok Bad Debt Expense
BadDebtExpense
0
CY2024Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
283283
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
361219
CY2024Q1 evok Non Rule10 B51 Arr Modified Flag
NonRule10B51ArrModifiedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
212467
CY2024Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
93026
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
120621
CY2024Q1 us-gaap Inventory Net
InventoryNet
588776
CY2023Q4 us-gaap Inventory Net
InventoryNet
481840
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
32327447
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
569351
CY2024Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
39414780
CY2024Q1 evok Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
33642722
CY2024Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
39414780
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
254029
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
284572
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
400000
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P0Y8M19D
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 evok Rule10 B51 Arr Modified Flag
Rule10B51ArrModifiedFlag
false

Files In Submission

Name View Source Status
0000950170-24-059596-index-headers.html Edgar Link pending
0000950170-24-059596-index.html Edgar Link pending
0000950170-24-059596.txt Edgar Link pending
0000950170-24-059596-xbrl.zip Edgar Link pending
evok-20240331.htm Edgar Link pending
evok-20240331.xsd Edgar Link pending
evok-ex31_1.htm Edgar Link pending
evok-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img216179745_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
evok-20240331_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable